Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Classmates motivate childhood cancer patients to participate in physical activity during treatment: A qualitative study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Psychotropic Medication Use in Parents of Children Diagnosed With Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to 12/2014, Nordic and Baltic centers treated 1509 consecutive patients aged 1-45 years with Philadelphia chromosome-negative ALL according to the NOPHO ALL2008 without cranial irradiation. Overall, 1022 patients were of age 1-9 years (A), 266 were 10-17 years (B) and 221 were 18-45 years (C). Sixteen patients (three adults) died during induction. All others achieved remission after induction or 1-3 intensive blocks. Subsequently, 45 patients (12 adults) died, 122 patients relapsed (32 adults) with a median time to relapse of 1.6 years and 13 (no adult) developed a second malignancy. Median follow-up time was 4.6 years. Among the three age groups, older patients more often had higher risk ALL due to T-ALL (32%/25%/9%, P<0.001), KMT2A rearrangements (6%/5%/3%, P<0.001) and higher day 29 residual leukemia for B-lineage (P<0.001), but not T-ALL (P=0.53). Event-free survival rates (pEFS5y) were 89±1% (A), 80±3% (B) and 74±4% (C) with significant differences only for non-high risk groups. Except for thrombosis, pancreatitis and osteonecrosis, the risk of 19 specified toxicities was not enhanced by age above 10 years. In conclusion, a pediatric-based protocol is tolerable and effective for young adults, despite their increased frequency of higher risk features.Leukemia advance online publication, 22 September 2017; doi:10.1038/leu.2017.265.

Original languageEnglish
JournalLeukemia
Volume32
Pages (from-to)606-15
ISSN0887-6924
DOIs
Publication statusPublished - 2018

    Research areas

  • Journal Article

ID: 52175161